Hangzhou Tigermed Consulting Co., Ltd.
Hangzhou Tigermed Consulting Co., Ltd.
Aktie · CNE100001KV8 (XSHE)
Übersicht
Kein Kurs
Schlusskurs XSHE 30.10.2025: 59,09 CNY
30.10.2025 07:04
Aktuelle Kurse von Hangzhou Tigermed Consulting Co., Ltd.
BörseTickerWährungLetzter UmsatzKursTagesveränderung
XSHE: SHENZHEN STOCK EXCHANGE
SHENZHEN STOCK EXCHANGE
300347.SZ
CNY
30.10.2025 07:04
59,09 CNY
-0,39 CNY
-0,66 %
Free Float & Liquidität
Free Float 84,86 %
Shares Float 626,2 M
Ausstehende Aktien 737,9 M
Investierte Fonds

Folgende Fonds haben in Hangzhou Tigermed Consulting Co., Ltd. investiert:

Fonds
iShares MSCI China UCITS ETF USD (Dist)
Vol. in Mio
0,69
Anteil (%)
0,02 %
Fonds
iShares MSCI EM ESG Enhanced UCITS ETF USD (Dist)
Vol. in Mio
40,02
Anteil (%)
0,01 %
Fonds
iShares MSCI EM ESG Enhanced UCITS ETF USD (Acc)
Vol. in Mio
168,53
Anteil (%)
0,01 %
Fonds
iShares MSCI EM IMI ESG Screened UCITS ETF USD (Acc)
Vol. in Mio
72,09
Anteil (%)
0,0046 %
Fonds
iShares MSCI EM IMI ESG Screened UCITS ETF USD (Dist)
Vol. in Mio
14,24
Anteil (%)
0,0046 %
Firmenprofil zu Hangzhou Tigermed Consulting Co., Ltd. Aktie
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Erhalte tagesaktuelle Insights vom finAgent über Hangzhou Tigermed Consulting Co., Ltd.

Unternehmensdaten

Name Hangzhou Tigermed Consulting Co., Ltd.
Firma Hangzhou Tigermed Consulting Co., Ltd.
Website https://www.tigermed.net
Heimatbörse XSHE SHENZHEN STOCK EXCHANGE
ISIN CNE100001KV8
Wertpapierart Aktie
Sektor Healthcare
Branche Medical - Diagnostics & Research
CEO Xiaoping Ye D.Phil, EMBA,
Marktkapitalisierung 52 Mrd.
Land China
Währung CNY
Mitarbeiter 10,2 T
Adresse F18, Building A – Shengda Science Park, 310051 Hangzhou
IPO Datum 2012-08-17

Ticker Symbole

Name Symbol
SHENZHEN STOCK EXCHANGE 300347.SZ
Weitere Aktien
Investoren, die Hangzhou Tigermed Consulting Co., Ltd. halten, haben auch folgende Aktien im Depot:
DEUTSCHE POST MTN.20/29
DEUTSCHE POST MTN.20/29 Anleihe
LBBW FZA 21/27
LBBW FZA 21/27 Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025